Immunohistochemical analysis of bcl-2 family proteins in benign and malignant ameloblastomas

Journal of Oral Pathology and Medicine

Volumn 28, Issue 8, 1999, Pages 343-349

  Kumamoto, Hiroyuki ^a   Ooya, Kiyoshi ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Ameloblastoma; Bax; Bcl 2; Bcl x; Immunohistochemistry; Malignant ameloblastoma

Indexed keywords

EID: 0033199484     PISSN: 09042512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0714.1999.tb02051.x     Document Type: Article

References (33)

1. KRAMER IRH, PINDBORG JJ, SHEAR M. The WHO histological typing of odontogenic tumours: a commentary on the second edition. Cancer 1992; 70: 2988-94.
2. SHEAR M. Developmental odontogenic cysts: an update. J Oral Pathol Med 1994; 23: 1-11.
3. KRAMER IRH, PINDBORG JJ, SHEAR M. WHO histological typing of odontogenic tumours. Berlin: Springer-Verlag, 1992: 11-4.
4. KUMAMOTO H, KAMAKURA S, OOYA K. Desmoplastic ameloblastoma in the mandible: report of a case with an immunohistochemical study of epithelial cell markers. Oral Med Pathol 1998; 3: 45-8.
5. KRAMER IRH, PINDBORG JJ, SHEAR M. WHO histological typing of odontogenic tumours. Berlin: Springer-Verlag, 1992: 25.
6. SLOOTWEG PJ. p53 protein and Ki-67 reactivity in epithelial odontogenic lesions: an immunohistochemical study. J Oral Pathol Med 1995; 24: 393-7.
7. KUMAMOTO H, OOYA K. Expression of E-cadherin and α-catenin in epithelial odontogenic tumors: an immunohistochemical study. J Oral Pathol Med 1999; 28: 152-7.
8. KERR JFR, WYLLIE AH, CURRIE AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-57.
9. CARSON DA, RIBEIRO JM. Apoptosis and disease. Lancet 1993; 341: 1251-4.
10. VAUX DL, CORY S, ADAMS JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-2.
11. HOCKENBERY D, NUNES G, MILLIMAN C, SCHREIBER RD, KORSMEYER SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-6.
12. YONISH-ROUACH E, RESNITZKY D, LOTEM J, SACHS L, KIMCHI A, OREN M. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 1991; 352: 345-7.
13. EVAN GI, WYLLIE AH, GILBERT CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69: 119-28.
14. TSUJIMOTO Y, COSSMAN J, JAFFE E, CROCE CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985; 228: 1440-3.
15. BOISE LH, GONZÁLEZ-GARCIA M, POSTEMA CE, et al. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608.
16. L and bcl-2 repress a common pathway of cell death. J Exp Med 1995; 182: 821-8.
17. OLTVAI ZN, MILLIMAN CL, KORSMEYER SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates program cell death. Cell 1993; 74: 609-16.
18. SEDLAK TW, OLTVAI ZN, YANG E, et al. Multiple bcl-2 family members demonstrate selective dimerizations with bax. Proc Natl Acad Sci USA 1995; 92: 7834-8.
19. SLOOTWEG PJ, DE VEGER RA. Immunohistochemical demonstration of bcl-2 protein in human tooth germs. Arch Oral Biol 1994; 39: 545-50.
20. MITSUYASU T, HARADA H, HIGUCHI Y, et al. Immunohistochemical demonstration of bcl-2 protein in ameloblastoma. J Oral Pathol Med 1997; 26: 345-8.
21. KUMAMOTO H. Detection of apoptosis-related factors and apoptotic cells in ameloblastomas: analysis by immunohistochemistry and an in situ DNA nick end-labelling method. J Oral Pathol Med 1997; 26: 419-25.
22. KRAJEWSKA M, FENOGLIO-PREISER CM, KRAJEWSKI S, et al. Immunohistochemical analysis of bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol 1996; 149: 1449-57.
23. LE BRUN DP, WARNKE RA, CLEARY ML Expression of bcl-2 in fetal tissues suggests a role in morphogenesis. Am J Pathol 1993; 142: 743-53.
24. KRAJEWSKI S, KRAJEWSKA M, SHABAIK A, et al. Immunohistochemical analysis of in vivo patterns of bcl-X expression. Cancer Res 1994; 54: 5501-7.
25. KRAJEWSKI S, KRAJEWSKA M, SHABAIK A, MIYASHITA T, WANG HG, REED JC. Immunohistochemical determination of in vivo distribution of bax, a dominant inhibitor of bcl-2. Am J Pathol 1994; 145: 1323-36.
26. WRONE-SMITH T, JOHNSON T, NELSON B, et al. Discordant expression of bcl-x and bcl-2 by keratinocytes in vitro and psoriatic keratinocytes in vivo. Am J Pathol 1995; 146: 1079-88.
27. L gene in human gastric adenomas and carcinomas. Int J Cancer 1996; 68: 727-30.
28. BARGOU RC, DANIEL PT, MAPARA MY, et al. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-α expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 1995; 60: 854-9.
29. JOENSUU H, PYLKKANEN L, TOIKKANEN S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994; 145: 1191-8.
30. BRONNER MP, CULIN C, REED JC, FURTH EE. The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol 1995; 146: 20-6.
31. KRAJEWSKA M, KRAJEWSKI S, EPSTEIN J, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996; 148: 1567-76.
32. KRAJEWSKI S, BLOMQVIST C, FRANSSILA K, et al. Reduced expression of proapoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995; 55: 4471-8.
33. MIYASHITA T, REED JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-9.